Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 68

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 68
---
.

After the special meeting held by Iris on December 20, 2024, to vote upon a charter amendment to extend the time to complete a business combination until March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board), public stockholders elected to redeem 64,453 shares of common stock, resulting in $2,001,033 of funds remaining in the Trust Account (as adjusted for redemptions paid out of the Trust Account in January 2025 and subject to adjustment for such further taxes as may be payable from the Trust Account) and 174,477 shares of Iris common stock held by the public stockholders.

Notwithstanding the foregoing, a holder of public shares, together with any of its affiliates or any other person with whom such holder is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Exchange Act) will be restricted from exercising redemption rights with respect to an aggregate of 15% or more of the public shares.

<div align='center'>7</div>

TABLE OF CONTENTS

Impact of the Business Combination on ParentCo’s Public Float The following table summarizes the pro forma equity ownership in ParentCo Common Stock immediately following the Business Combination under three redemption scenarios.

| ​                                 | ​ | ​ | Assuming NoAdditionalRedemptions(1)(2) |   |            |   | ​ | ​ | %Ownership |   |      |   | ​ | ​ | Assumingan additional50%Redemption(1)(3) |   |            |   | ​ | ​ | %Ownership |   |      |   | ​ | ​ | AssumingMaximumRedemptions(1) |   |            |   | ​ | ​ | %Ownership |   |      |   | ​ |
| Iris public stockholders          | ​ | ​ | ​                                      | ​ |    174,477 | ​ | ​ | ​ | ​          | ​ |  0.7 | ​ | ​ | ​ | ​                                        | ​ |     87,238 | ​ | ​ | ​ | ​          | ​ |  0.3 | ​ | ​ | ​ | ​                             | ​ |          0 | ​ | ​ | ​ | ​          | ​ |    0 | ​ | ​ |
| Sponsor and independent directors | ​ | ​ | ​                                      | ​ |  6,900,000 | ​ | ​ | ​ | ​          | ​ |